Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy

Summary

The purpose of this study is to determine the highest tolerated dose, safety and activity of HCD122 in patients with chronic lymphocytic leukemia who are relapsed after receiving prior treatment.

Timeline

Start

2005-04

Primary completion

2008-06

Completion

2008-06

Outcome

Outcome not reported

Stopped (Enrollment): “Slow enrollment and minimal preliminary biological and clinical efficacy.”

Drugs

Indications